Douglas Kerr, an officer of Dyne Therapeutics, Inc., filed a Form 144 notice on November 13, 2026, disclosing a proposed sale of 2,604 shares of common stock through Stifel Nicolaus & Company Inc.

Key Highlights

  • Proposed sale: Douglas Kerr intends to sell 2,604 shares of Dyne Therapeutics common stock with an aggregate market value of $43,810.00, according to the filing.
  • Approximate sale date: The filing lists November 13, 2026 as the approximate date of sale, with Nasdaq named as the securities exchange.
  • Source of shares: The 5,312 shares were acquired on November 13, 2026 through restricted stock units from the issuer, with payment characterized as equity compensation.
  • Shares outstanding: The filing reports 186,746,431 shares of common stock outstanding.
  • Broker: Stifel Nicolaus & Company Inc., 501 N Broadway, St. Louis, MO 63102, is named as the broker for the proposed sale.
  • Prior sales: The filing discloses two sales by Doug Kerr in the past three months: 3,745 shares sold on September 4, 2026, for gross proceeds of $91,187.00, and 1,290 shares sold on September 8, 2026, for gross proceeds of $24,360.00.

Kerr's Proposed Rule 144 Sale at Dyne Therapeutics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Douglas Kerr, identified as an officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), is proposing to sell 2,604 shares of the company's common stock. The filing lists an aggregate market value of $43,810.00 for the proposed sale and identifies Stifel Nicolaus & Company Inc. as the executing broker. The notice was signed by Azad Daswani as a duly authorized representative of Stifel, acting as attorney-in-fact for Doug Kerr.

The filing states that the 5,312 shares underlying the proposed sale were acquired on November 13, 2026 via restricted stock units granted by the issuer, with the nature of payment listed as equity compensation. Dyne Therapeutics is headquartered at 1560 Trapelo Road, Waltham, Massachusetts 02451, and its SEC file number is listed as 001-39509.

The filing also discloses sales by Doug Kerr over the prior three months: 3,745 shares sold on September 4, 2026, generating gross proceeds of $91,187.00, and 1,290 shares sold on September 8, 2026, generating gross proceeds of $24,360.00. These prior sales are reported at Kerr's address of 1560 Trapelo Rd, Waltham, MA 02451, consistent with the issuer's address.

What Was Disclosed

Dyne Therapeutics officer Douglas Kerr filed a Form 144 notice proposing the sale of 2,604 common shares with an aggregate market value of $43,810.00, acquired through restricted stock units, with an approximate sale date of November 13, 2026 on Nasdaq.